J.P. Morgan Day One: Biopharma Braces For Headwinds Ahead

 
• By Scrip Team
  
Generate a summary of this article
Listen to this article
Beta

Daily notebook from the J.P. Morgan Healthcare Conference: Turbulent weather matches sentiment about the year ahead, with investors looking for reassurance on the IRA, deal-making and growth strategy from big pharma. Updates from J&J, Biogen, BMS, Merck and more.

J.P. Morgan Daily Notebook: Day 1
• Source: Shutterstock

Johnson & Johnson CEO Joaquin Duato took time during the firm’s 9 January J.P. Morgan Healthcare Conference presentation in the Westin Grand Ballroom to clarify that the company wasn't interested in acquiring Horizon Therapeutics plc, even though J&J was named in a press release as one of several drug makers pursuing the company in December. Amgen, Inc. ultimately sealed a deal to buy Horizon for $27.8bn. (Also see "Amgen To Enhance Rare Disease Franchise With $27.8bn Horizon Takeover" - Scrip, 12 December, 2022.)

"I think it's important for investors to understand that Horizon Therapeutics was not a company that was in the sweet...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.